XD14

Cat. No. M28271

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.

XD14 is a potent BET inhibitor with antitumor effect. It binds to BRD2, BRD3, and BRD4 with Kds of 170, 380, and 160 nM, respectively.

Molecular Weight	421.51
Formula	C20H27N3O5S
CAS Number	1370888-71-3
Form	Solid
Solubility (25°C)	DMSO 125 mg/mL (ultrasonic)
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related Epigenetic Reader Domain Products
RVX-208 Apabetalone (RVX-208) is a first-in-class, small molecule inhibitor of BET bromodomain with IC50 of 0.51 μM for BD2.
I-BET151 I-BET151 (GSK1210151A) is an inhibitor of the BET family with IC50 of 0.5 μM, 0.25 μM and 0.79 μM for BRD2, BRD3 and BRD4, respectively.
(+)-JQ1 (+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway.
I-BET-762 I-BET-762 (GSK525762) is a selective small molecule BET inhibitor.
CPI-0610 CPI-0610 is a novel BET protein bromodomain inhibitor.

Catalog